Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 5;68(6):e0172023.
doi: 10.1128/aac.01720-23. Epub 2024 May 1.

Insights into the activity of cefiderocol against PER-2 producing Enterobacterales

Affiliations

Insights into the activity of cefiderocol against PER-2 producing Enterobacterales

Melina Ruggiero et al. Antimicrob Agents Chemother. .

Abstract

The PER-2 β-lactamase is a unique class A enzyme conferring broad spectrum cephalosporin resistance. In this study, we explored the stability of cefiderocol (FDC) against PER-2 β-lactamase to gain insights into structure activity relationships (SAR) of this synthetic siderophore-conjugated antibiotic. Herein, we show that the MICs of FDC for PER-2 producing isolates and transformants ranged between 0.125 and 64 µg/mL; diazabicyclooctanes (DBOs) reduced the MIC values. In PER-2 mutants, MIC values decreased up to 10-12 dilutions in agreement with previous observations especially in the case of Arg220 substitutions. Catalytic efficiency for PER-2 was 0.072 µM-1 s-1, comparable with PER-1 (0.046 µM-1 s-1) and NDM-1 (0.067 µM-1 s-1). In silico models revealed that FDC within the active site of PER-2 demonstrates unique interactions as a result of the inverted Ω loop fold and extension of the β3-β4 connecting loop.

Keywords: Arg220; ESBL; diazabicyclooctanes; docking; enzyme kinetics; siderophore-conjugated.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig 1
Fig 1
Upper panel: chemical structure of FDC. Middle panel: most energetically favorable conformations of FDC docked in the active site of PER-2: conformation 1: −9.1 kcal/mol; conformation 2: −8.5 kcal/mol. Lower panel: surface view showing the active site cavity of PER-2, colored according to hydrophobicity scale (red = hydrophobic; white = polar) and the two energetically favored FDC conformations.
Fig 2
Fig 2
In silico models of FDC docked into the active sites of PER-2 reveal the details of the non-covalent (Michaelis) complex of both possible conformations of FDC (cyan sticks), showing the main hydrogen bond interactions (dashed yellow lines). PER-2 residues are shown as orange sticks.
Fig 3
Fig 3
In silico models of FDC docked into the active sites of PER-2 demonstrating differential hydrogen bonds (dashed yellow lines) found in the acyl-enzyme complex of PER-2 with “conformation 1” or “conformation 2” (magenta sticks) of FDC. PER-2 residues are shown as orange sticks.
Fig 4
Fig 4
In silico models of FDC docked into the active sites of PER-2 and CTX-M-96. Left: comparison between the interaction of FDC and the main amino acids in the active site of PER-2 (orange sticks) and CTX-M-96 (gray sticks); only hydrogen bonds occurring with CTX-M-96 are shown (yellow dashed lines). Right: surface view of the active site residues of PER-2 (upper panel) and CTX-M-96 (lower panel), colored according to hydrophobicity scale (red = hydrophobic; white = polar).

References

    1. Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, Tsuji M, Yamano Y. 2016. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 60:7396–7401. doi:10.1128/AAC.01405-16 - DOI - PMC - PubMed
    1. Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, Kohira N, Miyagawa S, Ishibashi N, Matsumoto S, Nakamura R, Tsuji M, Yamano Y. 2018. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother 62:e01454-17. doi:10.1128/AAC.01454-17 - DOI - PMC - PubMed
    1. Tillotson GS. 2016. Trojan horse antibiotics—a novel way to circumvent Gram-negative bacterial resistance?. Infect Dis (Auckl) 9:45–52. doi:10.4137/IDRT.S31567 - DOI - PMC - PubMed
    1. Dobias J, Dénervaud-Tendon V, Poirel L, Nordmann P. 2017. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis 36:2319–2327. doi:10.1007/s10096-017-3063-z - DOI - PubMed
    1. Jacobs MR, Abdelhamed AM, Good CE, Rhoads DD, Hujer KM, Hujer AM, Domitrovic TN, Rudin SD, Richter SS, van Duin D, Kreiswirth BN, Greco C, Fouts DE, Bonomo RA. 2019. ARGONAUT-I: activity of cefiderocol (S-649266) a siderophore cephalosporin, against Gram-negative bacteria, including carbapenem-resistant nonfermenters and Enterobacteriaceae with defined extended-spectrum Β-lactamases and carbapenemases. Antimicrob Agents Chemother 63:e01801-18. doi:10.1128/AAC.01801-18 - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources